首页> 外文期刊>European urology >The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
【24h】

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours

机译:2016年世界卫生组织泌尿系统和男性生殖器官肿瘤分类-B部分:前列腺和膀胱肿瘤

获取原文
获取原文并翻译 | 示例
           

摘要

It has been 12 yr since the publication of the last World Health Organization( WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report. Patient summary: Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential. (C) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
机译:自从世界卫生组织(WHO)对前列腺和膀胱肿瘤进行最后分类以来,已经过去了12年。在这段时间里,有关这些肿瘤的病理学和遗传学的重要新知识已经产生。前列腺导管内癌是2016年WHO分类中新近认可的实体。在大多数情况下,它代表侵袭性前列腺癌的导管内扩散,应与高级前列腺上皮内瘤变分开。新的腺泡腺癌变体是微囊腺癌和多形巨细胞腺癌。对Gleason评分系统的修改已纳入2016年WHO关于前列腺癌分级的章节,并且建议应报告Gleason评分7的模式4的百分比。新的WHO分类进一步建议了最近开发的前列腺癌等级分组与五个年级组。对于膀胱癌,2016年WHO分类标准继续推荐1997年国际泌尿外科病理学学会分级分类。新近描述或更好定义的非侵入性尿路上皮病变包括尿路上皮发育不良和恶性潜能不确定的尿路上皮增生,这在有尿路上皮癌病史的患者中经常发现。具有不同分化的浸润性尿路上皮癌是指具有一定百分比的“正常型”尿路上皮癌与其他形态相结合的肿瘤。病理学家应在病理报告中提及不同组织学的百分比。患者摘要:前列腺导管内癌是2016年世界卫生组织分类中的一个新公认实体。定义更明确的非侵入性尿路上皮病变包括尿路上皮发育不良和恶性潜能不确定的尿路上皮增生。 (C)2016年欧洲泌尿外科协会。由Elsevier B.V.发布。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号